SRNE News and Press, Sorrento Therapeutics Inc. From 08/12/21

The Delta variant has demonstrated a likely course for our Covid future – a new endemic piece of the global human microbiome puzzle. It’s not the news we wanted. But it could have turned out a lot worse.  Covid is amenable to vaccine solutions, even if we may have to come u...

Sorrento to obtain exclusive rights in North and South America, Europe, major Asian countries (including Greater China and Japan) and certain other countries to utilize Dyadic’s C1 technology for the development and commercialization of vaccines, therapeutic antibodies, protein the...

Sorrento to obtain exclusive rights in North and South America, Europe, major Asian countries (including Greater China and Japan) and certain other countries to utilize Dyadic’s C1 technology for the development and commercialization of vaccines, therapeutic antibodies, protein t...

SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain and COVID-19, announced today the availability of a presentation on its corporate web...

SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), in collaboration with The Scripps Research Institute of La Jolla, today announced that the American Chemical Society has published the article “Salicylanilides Reduce SARS-CoV-2 Repli...

After COVI-STIX™ (COVID-19 VIRUS RAPID ANTIGEN DETECTION TEST) obtained Emergency Use Authorization (EUA) approval from the Mexican Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS), Sorrento and Mexican INMEGEN (“Instituto Nacional de Medici...

Sorrento Therapeutics (NASDAQ:SRNE) announces that the U.S. FDA has authorized the company's IND application for the Phase 1 clinical testing of its allogeneic anti-CD38 Dimeric Antigen Receptor (DAR) - T Cell therapy for relapsed or refractory multiple myeloma. The company highlighted t...

First allogeneic, off-the-shelf anti-CD38 DAR-T cell therapy cleared for Phase 1 clinical trial in Relapsed or Refractory Multiple Myeloma. CD38 DAR-T is the first allogeneic, off-the-shelf clinical-stage cellular therapy product candidate based on Sorrento’s proprietary Dimeri...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Atossa Therapeutics (NASDAQ: ATOS ) is a highly intriguing company that has a great deal of potential. I recommend, however, that investors avoid taking a bullish position in ATOS stock for now. Source: CI Photos /...

Sorrento Therapeutics is ready to market the COVI-STIX in Mexico with 25 million test units. The company is planning to file a Biologics License Application for the Infliximab biobetter in the US and the EU. Short interest at 52-week low. For further details see: Sorrent...